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INTRODUÇÃO 
O fenômeno de Raynaud (FRy), como descrito em 1862 por 
Maurice Raynaud, caracteriza-se por episódios reversíveis de 
vasoespasmos de extremidades, associados a alterações de 
coloração típicas que ocorrem após exposição ao frio ou em 
situações de estresse.1,2 Geralmente ocorre em mãos e pés e em 
casos mais graves pode também acometer o nariz, orelhas ou 
língua. As alterações de coloração são classicamente descritas 
em três fases sucessivas: palidez (fase isquêmica), cianose 
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RESUMO
O fenômeno de Raynaud (FRy) caracteriza-se por episódios re-
versíveis de vasoespasmos de extremidades, associados a palidez, 
seguido por cianose e rubor de mãos e pés, que ocorrem usualmente 
após estresse ou exposição ao frio. O FRy primário é um evento fun-
cional benigno e não está associado a nenhuma doença ou condição 
subjacente. Já o FRy secundário pode estar associado a uma série de 
condições, principalmente a doenças reumáticas autoimunes. Na es-
clerose sistêmica (ES), o FRy é a manifestação inicial mais frequente. 
No FRy secundário às doenças do espectro da ES, complicações como 
lesões isquêmicas de extremidades são frequentes. Nos últimos anos, 
avanços no estudo da fisiopatologia do FRy e da doença vascular na ES 
propiciaram o surgimento de opções terapêuticas bastante promissoras 
para essa manifestação. Nesta revisão pretendemos discorrer princi-
palmente sobre a patogênese, a investigação clínica e o tratamento 
do FRy, com ênfase nos novos tratamentos disponíveis.
Palavras-chave: Esclerose sistêmica, fenômeno de Raynaud, trata-
mento, revisão.
ABSTRACT
Raynaud’s phenomenon (RP) is an episodic vasospasm of the periph-
eral arterioles, causing pallor followed by cyanosis and redness of 
the fingers and toes, usually in response to stress or cold exposure. 
Primary Raynaud’s phenomenon is a benign event and occurs without 
an underlying disease. In contrast, secondary Raynaud’s phenomenon 
can occur in association with several underlying diseases or condi-
tions, mostly autoimmune rheumatic diseases. In systemic sclerosis 
(SSc), RP is the most frequent initial manifestation. In RP secondary to 
SSc-related diseases, digital ischemic lesions are a frequent problem. 
In recent years, advances in the understanding of the physiopathology 
of RP have favored the development of novel promising therapeutic 
alternatives for this clinical condition. This article presents a review 
of the pathogenesis, clinical investigation and treatment of RP, with 
special emphasis in novel therapeutic modalities. 
Keywords: Systemic sclerosis, Raynaud´s phenomenon, treatment, 
review 
(causada por venoestase e desoxigenação) e rubor (hiperemia 
reativa/reperfusão).2,3 Dor e/ou parestesias podem também estar 
associadas aos ataques, causando desconforto ao indivíduo. 
O FRy é uma desordem relativamente comum e, na grande 
maioria dos casos, caracteriza-se por ser um evento funcional 
benigno, não havendo qualquer doença subjacente, sendo 
assim chamado de FRy primário ou idiopático.2 O FRy pode, 
no entanto, ser secundário a uma série de condições locais ou 
sistêmicas, destacando-se as doenças reumáticas autoimunes, 
o que torna esse tema de especial interesse para o reumatolo-
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medicamentosa com vasodilatadores, o princípio básico para o 
tratamento de úlceras de extremidades em pacientes com FRy 
inicia-se com debridamento e limpeza adequada das lesões, 
seguido do uso de curativos oclusivos e antibioticoterapia 
quando necessário. Curativos oclusivos podem ser úteis tanto 
para a proteção de áreas suscetíveis a traumas assim como para 
a cicatrização de úlceras.57 Curativos tópicos de hidrocoloide 
se mostraram seguros e eficazes em promover a cicatrização 
de úlceras digitais em um ensaio controlado e randomizado.58 
Pacientes com isquemia sustentada podem requerer hospita-
lização para tratamento mais agressivo. Anticoagulação com 
heparina por 24-72 horas pode ser considerada para casos de 
eventos isquêmicos agudos com rápida evolução.37
TRATAMENTO CIRÚRGICO
Simpatectomia deve ser reservada para pacientes com FRy 
grave com complicações associadas que não responderam ao 
tratamento medicamentoso. O efeito costuma ser temporário, 
principalmente em pacientes com FRy secundário à ES. Sim-
patectomia digital ou simpatectomia química com lidocaína 
ou bupivacaína pode ser utilizada em pacientes com isquemia 
crítica e úlceras ativas que não responderam ao tratamento 
farmacêutico. Simpatectomia cervical é relacionada a compli-
cações pós-operatórias, como síndrome do martelo hipotenar 
e neuralgia e é raramente recomendada.38
CONCLUSÕES
O fenômeno de Raynaud é relativamente frequente na popula-
ção geral, sendo importante a diferenciação entre FRy primário 
e secundário. O tratamento do FRy tem sofrido avanços com 
o advento de novas drogas com potente ação vasodilatadora. 
No entanto, proteção ao frio e uso de bloqueadores do canal de 
cálcio são ainda os tratamentos de primeira escolha. Associação 
terapêutica e novas drogas vasodilatadoras devem ser utilizadas 
em pacientes que não responderam às medidas iniciais e às dro-
gas bloqueadoras de canal de cálcio. Novas alternativas, como 
os antagonistas dos receptores de endotelina 1, os inibidores da 
fosfodiesterase V e os análogos da prostaciclina parecem ter 
lugar no manejo de úlceras isquêmicas de difícil tratamento, 
principalmente em pacientes com ES.
Raynaud´s phenomenon
INTRODUCTION
Raynaud’s phenomenon (RP), as described in 1862 by Maurice 
Raynaud, is characterized by reversible episodes of vasospasm 
of extremities, associated with changes in color that typically 
occur after exposure to cold or in stress situations.1,2 It gene-
rally occurs in the hands and feet and in more severe cases, 
can also attack the nose, ears or tongue. The changes in color 
are classically described in three successive phases: paleness 
(ischemic phase), cyanosis (caused by venostasis and deoxy-
genation) and redness (reactive hyperemia/reperfusion).2,3 Pain 
and/or paresthesias that cause discomfort to the individual can 
also be associated with the attacks. 
RP is a relatively common disorder and, in most cases, is a 
benign functional event, without any underlying disease, being 
called primary or idiopathic RP.2 However, RP can be seconda-
ry to several local or systemic conditions, mostly autoimmune 
rheumatic diseases, which make this a theme of special interest 
to the rheumatologist. Especially in RP secondary to systemic 
sclerosis (SSc), the vasospastic events are usually more intense 
and frequent, and often associated with ischemic ulcers and 
progressive resorption of the extremities. 
Recently, new insights into the pathogenesis of RP and the 
vascular disease in the SSc have led to the development of new 
therapeutic options for this manifestation. In this review, we 
intend to discourse mainly about the pathogenesis, the diag-
nosis investigation and the treatment of RP, with emphasis on 
novel treatments available.
EPIDEMIOLOGY
RP is relatively frequent, occurring around 3,5 to 15% of the 
general population.4-6 Differences found in the prevalence of RP 
result from the criteria used for the diagnosis, geographic and 
climatic variations, as well as population distinctive features. 
It is more common in women, young individuals, and among 
members of the same family. In a study conducted in the Uni-
ted States with Caucasian patients, the prevalence of RP was 
11% in women and 8% in men,7 while in another study with 
adolescents the prevalence was 15% in the female sex.8 The 
average age for the onset of primary RP is 14 years of age, and 
only 27% begin around 40 years of age or later.9 In contrast, 
the secondary RP tends to begin in adult life. The frequency 
and severity of the episodes are influenced by daily variations 
in temperature with sharp exacerbation during winter.7
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PATHOGENESIS
Although the pathogenesis of RP is not yet completely unders-
tood, several mechanisms involved in the vasospastic events 
are recognized (Figure 1). The vascular tonus is controlled 
by a complex interaction between endothelial cells, smooth 
musculature of the vascular wall, soluble mediators and neu-
ronal stimulation. An unbalance between vasoconstriction and 
vasodilatation, in favor of vasoconstriction, is a central event in 
the physiopathology of RP.10 It should be remembered that the 
alterations found vary according to the presence or not of an 
associated disorder. While primary RP is related to functional 
alterations alone,in RP secondary to SSc, structural alterations 
of the vascular wall are also found.3
The α2-adrenergic receptors are the main mediators of the 
vasoconstriction induced by cold in the smooth musculature 
cells.11 Hyperactivity of the α2-adrenoceptor and alteration in 
the production of neuropeptides (e.g. calcitonin gene-related 
peptide), are some of the mechanisms involved in the vasos-
pasm episodes induced by cold in primary and secondary RP.12 
Moreover, the endothelium plays an active role in regulating 
vascular tone. The endothelial cells produce a number of 
vasodilatory mediators, including endothelin, nitric oxide 
(NO), prostacyclin, and also vascular adhesion molecules. 
Releasing these mediators is a delicately regulated process in 
healthy individuals.13 In RP, especially when secondary to SSc, 
endothelial lesion and activation cause an imbalance between 
the production of vasoconstrictors and vasodilatory mediators, 
with an increase in the production of endothelin-1 (powerful 
vasoconstrictor) and a decrease in the production of NO and 
prostacyclin (vasodilating agents).10 The vasodilating effect of 
the NO and the prostacyclins occur through the cyclic AMP 
and cyclic GMP, being its degradation controlled by many 
phosphodiesterases.14 This fact has been explored from the 
therapeutics point of view with the using of phosphodiaste-
rase V (e.g. sildenafil) and prostacyclin analogs. On the other 
hand, the production blockage of vasoconstricting substances 
has been also explored, with the use of endothelin-1 receptors 
antagonists (e.g. bosentana).
Besides the functional and contractile alterations, struc-
tural alterations are found in secondary RP, mainly in SSc. 
Proliferation and intimal fibrosis of the small arteries and 
arterioles result in decrease of vessel lumen; these alterations 
cause decrease of blood flow and lead to a state of chronic 
ischemia of the involved organs.15, 16 In the microcirculation, 
capillary loss and dilatation are the most remarkable feature 
and lead to an important distortion of the capillary vascular 
architecture. The alterations in the microcirculation are also 
frequently associated with intravascular thrombus, which can 
cause a complete obstruction of the vessel lumen. This state of 
tissue hypoperfusion should favor the neoangiogenesis, howe-
ver, the formation of new capillaries is rarely observed, being 
usually observed large avascular areas, suggesting defects in 
the angiogenesis or in the vascular repair.12 This observation is 
possibly related to the reduction of VEGF (vascular endothelial 
growth factor), which would be important to the repopulation 
of capillary in the affected tissues. In fact, in a recent study of 
gene expression with cDNA microarray platform, our group de-
monstrated a significative decrease in the expression of VEGF 
gene by dermal fibroblasts of patients with SSc compared to 
cells of healthy controls.17 
In this context, the vasospasm of RP secondary to SSc is 
usually more serious, leading to reperfusion-ischemia episo-
des. It is suggested that in SSc, it’s suggested that the repeated 
episodes of reperfusion-ischemia cause an increase in free 
radicals activity (oxidative stress) and a persistent activation 
of the endothelial system.10 These factors could predispose to 
new vasospastic episodes, and so creating a vicious circle in 
which exists vasospasm, generation of free radicals, endothelial 
lesion and more vasospasm.16,18
↑ Vasoconstriction
↑ Reactivity of the 
adrenoreceptors α2 of the 
smooth musculature
↑ Endothelin-1
Oxidative stress
↓ NO and 
prostaciclin
↑ Platelet activation
↓ Fibrinolysis
↓ Deformation capacity of 
the red blood cells 
↑ Viscosity
Endothelial damage
↓ Vasodilation
↓ Vasodilating 
Neuropeptides
Reduced blood flow / 
procoagulating tendency
Smooth 
muscle  
cells
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Figure 1. Pathogenic mechanisms of Raynaud’s phenonomenon. Adapted from 
Herrick, 2005.10
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Finally, several intravascular abnormalities, such as platelet 
activation, increase of the fibrinolysis, leukocyte activation, 
and reduction of the deformation capacity of the red blood 
cells have been implicated as coadjuvant factors in the RP 
pathogenesis.10,18-21
CLINICAL INVESTIGATION OF 
RAYNAUD’S PHENOMENON
In clinical practice, it’s of extreme importance to differentiate 
patients with primary and secondary RP and predict which 
patients with RP will evolve to some other disease, mainly 
the rheumatic autoimmune diseases. This differentiation is 
extremely important to define the severity, prognostic factors 
and the most adequate treatment. In this context, all patients 
should be submitted to a thorough clinical history and physical 
exam. On top of that, we recommend performing a periungueal 
capillaroscopy, search for antinuclear antibodies (ANA) and 
inflammatory markers in all cases.2
The primary RP occurs generally in young women and 
about 25% of the patients have a family history of RP in 
first degree relatives.22 In primary RP the attacks are usually 
symmetric and less severe. Necrosis, ulceration, gangrene or 
reabsorption of of the affected extremities are not observed. 
The erythrocyte sedimentation rate (ESR) is usually normal. 
The periungueal capillaroscopy (PUC) is also usually normal, 
but eventually can be observed some ectasiated capillary. The 
ANA is usually negative (Table 1).2 However, it should be 
remembered that about 10% of the population have a positive 
ANA. In this context, the titer and morphologic pattern of the 
ANA are important criteria to be evaluated. In general, the ANA 
found in healthy people and in patients with primary RP shows 
low titers (up to 1:160). The main patterns of fluorescence are 
the nuclear fine speckled and the dense fine speckled. The latter 
deserves a special attention, as it usually is not associated with 
autoimmune systemic diseases, even when in high titers. 
As highlighted before, RP is considered to be secondary 
when it is associated with some underlying condition or dise-
ase; and among the causes of secondary RP, the autoimmune 
rheumatic diseases are emphasized (Table 2).23 RP is present 
in more than 90% of the patients with SSc, in approximately 
85% of the patients with mixed connective tissue disease, in 
10 to 45% of the patients with systemic lupus erythematosus, 
in 33% of those with Sjögren’s syndrome, in 20% of the cases 
of dermatomyositis or poliomyositis, and also in 10% of the 
cases of rheumatoid arthritis.24
It is also known that approximately 10% of the patients with 
an initial diagnosis of primary RP developed subsequently a 
rheumatic autoimmune disease, being of fundamental impor-
tance the identification of the patients with significative risk 
for the developing of such conditions (Table 3).25 Especially 
in diseases of the SSc spectrum, RP can be an initial isolated 
manifestation, preceding for years or even decades the other 
manifestations of the disease. A secondary cause for RP should 
be suspected in the presence of very intense episodes of RP, if 
the beginning of the symptoms happens after the 30 years of 
age and in the presence of trophic alterations on the extremities, 
such as cutaneous thickening, digital pulp atrophy, microscars 
Table 2
Causes for secondary Raynaud`s phenomenon
Rheumatic diseases Systemic sclerosis
Mixed Connective Tissue Disease
Systemic Lupus Erythematosus
Sjögren syndrome
Dermatomyosites
Rheumatoid arthritis
Vasculitis
Drugs and toxic agents Beta blockers (including in ocular solution)
Ergot derivated susbtances
Cancer chemotherapy
Ciclosporin
Interferon α and β
Cocaine
Tobbacco adiction (probable)
Endocrine diseases Hypothyiroidism
Pheochromocytoma
Carcinoid syndrome
Trauma or lesion of 
the great vessels
(unillateral Raynaud)
Lesion by use of vibratory instruments
Ulnar aneurism (Hypothenar 
hammer syndrome)
Thoracic outlet syndrome
Arterial disease Thromboangiites obliterans
Atheroma
Peripheral embolism
Hemathologic disorders
Neoplasias
Crioglobulinemia
Policitemy
Mielo and lymphoproliferative diseases
Ovary carcinoma
MCTD = Mixed Connective Tissue Disease; SLE = Systemic Lupus Erythematosus
Table 1
Diagnostic criteria for primary Raynaud`s phenomenon
Episodic attacks of pallor or cyanosis of extremities
Strong and symetric peripheric pulses
Absence of microscars, ulcers or digital gangrene
Normal periungueal capillaroscopy
Normal erythrocyte hemosedimentation rate (< 20 mm/hour)
Absence of antinuclear antibodies (ANA titers < 1:100)
Adapted from LeRoy and Medsger, 1992.
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Figure 2. Periungueal capillaroscopy with normal capillaroscopic pattern (capilla-
ries with homogeneous shape, size and distribution) (A), and with microangiopathy 
SD pattern (dilated capillaries in devascularization areas) (B).
A
B
or digital ulcers.26 On top of that, a series of prospective studies 
with individuals with RP also demonstrates that abnormal 
findings at the periungueal capillaroscopy and/or the presen-
ce of some autoantibodies in high titers identify a group of 
patients with a high risk of developing systemic sclerosis and 
correlated diseases.27-31 In individuals with an isolated RP, the 
pattern SD to PUC presents a positive predictive value for the 
developing of an autoimmune rheumatic disease around 50% 
and a negative predictive value of more than 90%. 
The PUC is a noninvasive test, considered an important 
method for identification of morphologic alterations in the 
microcirculation in diseases associated with the SSc spec-
trum.32 In primary RP, the PUC presents a pattern similar to 
normal, that is, presence of capillaries loops of homogeneous 
size, shape and color transversally disposed along the cuticle 
(Figure 2A).33 Some dilated capillaries can be found. While 
in RP associated with diseases of the SSc spectrum, the PUC 
presents a microangiopathic scenario denominated SD pattern, 
which is characterized by the presence of capillary dilation and 
distortion associated with areas of devascularization (Figure 
2B).34 The presence of micropetechiae of disseminated distribu-
tion is also associated with SD pattern. SD pattern is described 
mainly in the SSc, dermatomyositis, mixed connective tissue 
disease and overlapping SSc syndromes. It is also described 
in 5-10% of the patients with systemic lupus erythematosus, 
representing a subgroup of patients characterized by presenting 
sausage fingers, esophageal dismotility, RP and antibodies 
anti-U1-RNP.35 
The presence of ANA has a positive predictive value rela-
tively low for the development of an autoimmune rheumatic 
disease (30%);25 notwithstanding, the presence of an antibody 
against some specific autoantigens is much more suggestive of 
a secondary cause.31 When analyzing the ANA test, facing a 
positive result, a fundamental point for the correct appreciation 
of the test is the evaluation of titer and fluorescence pattern. 
Fluorescence pattern might suggest some specificity of auto-
antibodies, guiding the doctor on the suspect diagnosis or on 
the next steps of the laboratorial investigation. However, it is 
pointed out that to most autoantibodies, the information from 
fluorescence pattern is just a preliminary guide, the specificity 
of the antibody should be confirmed by other immunological 
methods, since the finding of some autoantibodies have a 
diagnostic and prognostic stronger value. Among these, stand 
Table 3
Main differences between primary and 
secondary Raynaud`s phenomenon
Primary Secondary
Prevalence Common Rare
Association with AIRD No Yes
Associated to ANA No Generally
Microangiopathy in PUC No Generally
RP family history Yes No (occasionaly)
Pharmacological treatment No (occasionaly) Frequentely
Complications No (rarely) Yes
AIRD = Autoimmune rheumatic disease; ANA = Antinuclear antibody. PUC = Periungueal 
capillaroscopy.
Adapted from Block and Winston Sequeira, 2001.
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out in the context of SSc, the antibodies anticentromere, anti-
DNA topoisomerase I (Scl-70), anti-RNA polymerases I and 
III, and antifibrilarin. In the context of the systemic lupus 
erythematosus, the antibodies native anti-DNA, antinucleo-
some, anti-Sm, antiprotein P ribosomal and anti-PCNA are 
relevant due to high specificity. The antibody anti-U1-RNP 
strongly favors an autoimmune rheumatic disease, including 
mixed connective tissue disease, systemic lupus erythematosus 
and SSc itself. Although the antibody anti-PM-Scl is frequently 
found in the overlapping syndrome, it can also be eventually found 
in patients with an isolated SSc.
According to the indication of the initial clinical test, the 
performance of more specific test to evaluate the esophageal 
involvement (esophagogram, esophageal manometry, esopha-
geal cintilography) and pulmonary involvement (simple radio-
graphy, pulmonary function tests, high resolution computed 
tomography, echocardiography) can be useful, being these 
organs frequently compromised in SSc. 
It should also be investigated the use of drugs which can 
induce to RP (e.g. cyclosporine and nonselective beta blockers), 
exposure to toxic agents, specially chemotherapy and a history 
of repetitive traumas, mainly vibrational ones. 
Finally, the presence of unilateral RP suggests an occu-
pational lesion or disease (e.g. workers who use vibratory 
instruments or are exposed to high frequencies for long periods 
of time). The thoracic outlet syndrome manifests itself via neu-
rological symptoms and vascular compression associated with 
unilateral RP in 45% of the cases. The investigation should be 
complemented with image tests (radiography of the cervical 
spine, angiography or magnetic resonance imaging). Whereas 
the hypothenar hammer syndrome is related with a dysplasia of 
the anterior ulnar artery, with formation of an aneurysm which 
later suffers a thrombosis, resulting in a constant “hammering” 
over the hands volar face, with the possibility of evolving with 
numbness, discoloration of the hands and even formation of an 
ulcer on the tip of the fingers. The diagnosis can be clinically 
confirmed by the Allen test, or by an ultrasound with Doppler 
or arteriography.3 
TREATMENT
In individuals with primary RP pharmacological treatment is 
not generally necessary, general measures such as avoiding 
cold exposure and patient education are usually adequate.36 
On the contrary the RP secondary to rheumatic autoimmune 
diseases will often need drug treatment. In theses cases, the 
severity and complications associated should be evaluated and 
the treatment should be stratified for each case. Other causes, 
if identified (e.g. thoracic outlet syndrome), should also be 
adequately treated. The objective of the treatment should be 
to decrease the severity and the number of RP episodes and to 
prevent new ischemic lesions. Some authors believe that even 
patients with SSc with less severe RP episodes should be trea-
ted to prevent repeated episodes of ischemia reperfusion, but 
there is not an agreement regarding this orientation. However, 
patients with a history or evidence of ischemic lesions, such 
as ulcers or microscars of the digital pulp, should be treated 
this way.37 We will discuss in detail the treatment of RP asso-
ciated with autoimmune rheumatic diseases, mainly to SSc, 
since most of the clinical trials were performed in this group 
of patients (Table 4).
NONPHARMACOLOGICAL THERAPY 
Patients with mild RP may be managed just with cold protec-
tion measures. Higher temperatures are considered the best 
treatment to RP. In this context, all the patients should avoid 
exposure to cold and wear warm clothes, besides gloves, 
hood etc. It should also be avoided the use of agents that in-
duce important vasoconstriction like sympaticomimetic drugs, 
clonidin, ergotamine, caffeine and beta blockers. Control of 
emotions and anxieties through therapies that reduce stress can 
have a benefic effect, since stress can unleash or aggravate the 
vasoconstriction. Smoking cessation is essential in patients 
with SSc.37,38
Table 4
Pharmacologic treatment of Raynaud’s phenomenon
Dosage Effectiveness
CCB
Nifedipine 10-30 mg 3-4x/day  ++
Anlodipine 2.5-10 mg/day  ++ 
Diltiazen 30-90 mg 3-4x/day  +/-
Captopril 12.5-25 mg 3x/day  +/-
Losartan 50 mg/day  +/-
Sympatolitics
Prazosin 1-5 mg 2-3x/day ++
Pentoxifiline 400 mg 3x/day  +/-
Fluoxetine 20 mg/day  +/-
Endovenous prostaglandins
Bosentan 62.5-125 mg/day  ++
Sildenafil 12.5-100 mg/day  +
CCB = Calcium channel blockers
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Some alternative therapies like acupuncture, low frequency 
laser therapy and gloves impregnated with ceramic showed 
insufficiently expressive results.
PHARMACOLOGICAL THERAPY
Calcium channel blockers. The calcium channel blockers are 
vasodilating drugs, considered the first choice in the treatment 
of RP. Nifedipine is the most used drug, and it is considered 
effective for the treatment of RP primary and secondary to SSc. 
It should be given preference to the slow release formulations 
(SR). In two metanalysis performed by Thompson et al. the 
authors found a moderate reduction in the average number of 
attacks and an improvement of 33% and 35% in the severity of 
primary RP and associated to SSc, respectively.39,40 Recently, 
our group also evaluated the acute effect of nifedipine on the 
test of lacticemia of digital pulp before and after cold stimulus 
(LDP-CS) in a randomized, double-blind and placebo-control-
led clinical trial with a cross-over design in 20 patients with 
primary RP and 20 with SSc. We observed a benefic effect of 
the sublingual nifedipine on the microcirculation, mainly in the 
group of patients with SSc.41 Adverse effects include hypoten-
sion, headache and lower extremity edema. It should also be 
remembered that the calcium channel blockers can worsen the 
reflux symptoms since they reduce the pressure of the lower 
esophagean sphincter. The third generation of dihydropiri-
dines (amlodipine, felodipine) appears to be as effective as 
nifedipine;37 besides, they present a longer half-life than other 
dihydropiridines, enabling their administration in a single daily 
dose. Diltiazem and verapamil are less effective.3
ACE inhibitors and angiotensin II receptor antagonists. 
The ACE inhibitors changed dramatically the course of sclero-
derma renal crisis. However, studies that evaluated captopril or 
enalapril in the treatment of RP showed modest or inconclusive 
results, mainly in patients with SSc.37 A recent randomized, 
multicentric, placebo-controlled trial with 210 patients with 
limited SSc or RP in the presence of specific autoantibodies, 
did not show benefits after two to three years of treatment with 
quinapril on the occurrence of digital ulcers and other periphe-
ral vascular manifestations.42 Losartan 50 mg/day was better 
than nifedipine 40 mg/day in decreasing attack frequency and 
severity and also improved vascular parameters, most notably 
in patients who had primary RP, the results were marginal in 
patients with RP secondary to SSc.43 Our group also found 
modest results with losartan 50-100 mg/day in an open study, 
with 10 patients with SSc.44
Nitrates. Topic nitroglycerin seem to be effective and is an 
option for the treatment of patients with RP secondary to SSc. 
Nevertheless, the nitroglycerin possesses a vasodilating action 
and even its topic use can cause side effects such as headache 
and cutaneous rash.45
Alpha-adrenergic blockers. Few studies evaluated the 
α-adrenergic blockers in patients with RP.38 In a Cochrane 
review, two studies showed modest results with prazosin for 
the treatment of RP. Hypotension is a frequent side effect.46 
In a more recent study, a selective blocker α2c -adrenergic re-
ceptor antagonist (OPC-28326), significantly improved digital 
perfusion in patients with RP secondary to SSc.47
Serotonin antagonists. The serotonin is a vasoconstricting 
mediator and, because of that, its antagonists could have a 
beneficial effect in patients with RP.48 Still, the ketanserin was 
not effective in the treatment of patients with RP secondary to 
SSc.38 While fluoxetine, a selective serotonin reuptake inhibi-
tor, showed beneficial effects on the number and severity of 
RP attacks in a controlled study.49
Prostaciclin analogs. Prostaglandins are potent vasodila-
ting agents used in the treatment of pulmonary hypertension, 
that also inhibit platelet aggregation, have an antiproliferative 
effect in smooth muscular cells, and other biological properties, 
which can increase the vascular permeability.38 Although still 
rare in our country, the prostanoids under endovenous form 
(iloprost, alprostadil, epoprostenol) are extensively used in 
Europe and in the United States for the treatment of severe RP, 
with ischemia or digital ulcers.38,48 Intravenous administration 
of iloprost has been repeatedLy shown to improve severe 
Raynaud’s attacks and ischemic ulcerations.50,51 However the 
prostaciclin analogs with oral preparation are not effective.52 
Endothelin receptors antagonists. Endothelin is a powerful 
vasoconstricting agent, strongly implicated in the SSc patho-
genesis. Bosentan is an oral endothelin receptor antagonists, 
effective in the treatment of pulmonary hypertension. Two 
multicentric, double-blind and placeo-controlled trials, (RA-
PIDS-1 and RAPIDS-2) were performed with a large number 
of patients to evaluate the effectiveness of bosentan in the tre-
atment and prevention of the ischemic acute ulcers in patients 
with SSc.53,54 The RAPIDS-1 study showed that bosentan was 
effective in the prevention of new digital ulcers (an average of 
48% less than placebo). Hand function improved, but there was 
no effect on healing of preexisting ulcers (secondary endpoint). 
RAPIDS-2 was a study involving a larger number of patients 
that confirmed the findings of RAPIDS-1 in relation to the 
prevention of new ulcers. The use of this substance should be 
considered in patients with an important vasculopathy, with 
recurrent refractory ulcers.38 Recently, our group used Bosen-
tan in three patients with SSc and with refractory extremities 
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ulcers. We obtained cicatrization or diminution of the diameter 
of all the ulcers after 8 weeks of treatment.
Phosphodiesterase inhibitors. Sildenafil is a vasodilating 
agent used also in the treatment of pulmonary hypertension. 
Studies with a small group of patients showed an improve-
ment of RP and ischemic ulcers.38 In a double-blind, placebo-
controlled study with sildenafil 100 mg/day in patients with 
secondary RP, the authors observed an improvement of the 
symptoms and of the blood flow after 4 weeks of treatment.55 
Cilostazol, an inhibitor of phosphodiesterase type 3, didn’t 
show improvement in the symptoms or in the blood flow of 
the microcirculation after six weeks of treatment.56 Studies 
with a larger number of patients are necessary to confirm the 
real effectiveness of this group of drugs.
Antiaggregating and others. Although there is no evidence 
of its benefits, the use of low doses of aspirin (100 mg/day) is 
recommended to patients with SSc, mainly those with recurrent 
ulcers or episodes of important digital ischemia. As the oxi-
dative stress plays an important roll in the pathogenesis of the 
SSc, the use of antioxidant agents has been the object of some 
studies, although there is controversy, they seem useful mainly 
in early phases of the disease, before the establishment of irre-
versible vascular lesions, in association with other therapeutic 
modalities. Finally, it should be mentioned the pentoxifilin, an 
agent with the capacity of improving the rheologic characte-
ristic of blood (increases the flexibility of the erythrocytes and 
decreases the blood viscosity). It can be used in combination 
with other vasodilating agents. However, it needs controlled 
clinical trials to demonstrate its real effectiveness.37,38
ISCHEMIC ULCERS TREATMENT 
A frequent complication in RP secondary to SSc are the ex-
tremities ulcers, which generally are intensely painful and 
disabling, and can evolve with a secondary infection, gangrene 
and even amputation. Besides the pharmacological therapy 
with vasodilating agents, the basic principle for the treatment 
of extremities ulcers in patients with RP begins with the de-
bridement and adequate cleaning of the lesions, followed by 
the use of occlusive curatives and antibioticotherapy when 
necessary. Occlusive curatives can be useful to protect the 
susceptible areas from traumas as well as to the cicatrization 
of ulcers.57 Topic curatives of hydrocolloid showed to be safe 
and effective in promoting the cicatrization of digital ulcers 
in a controlled and randomized trial.58 Patients with sustained 
ischemia can require hospitalization for a more aggressive 
treatment. Anticoagulation with heparin for 24-72 hours can 
be considered for cases of acute ischemic events with fast 
evolution.37
SURGICAL TREATMENT
Simpathectomy should be reserved to patients, with severe 
RP and associated complications, who did not respond to drug 
treatment. The effect is usually temporary, mainly in patients 
with RP secondary to SSc. Digital sympathectomy or chemical 
sympathectomy with lidocaine or bupivacain can be used in 
patients with critical ischemia and active ulcers, did not respond 
to pharmaceutical treatment. Cervical sympathectomy is rela-
ted to postsurgical complications such as hypothenar hammer 
syndrome and neuralgy and is rarely recommended.38
CONCLUSIONS
Raynaud`s phenomenon is relatively frequent in general po-
pulation, being important the differentiation between primary 
and secondary RP. The treatment of RP has advanced with 
the advent of novel drugs with potent vasodilating action. 
However, protection from cold and the use of calcium chan-
nels blockers are still the first choice treatment. Therapeutic 
associations and novel vasodilating drugs should be used in 
patients who did not respond to the initial measures and to the 
calcium channel blocking drugs. New alternatives, like the 
endothelin 1 receptors antagonists, the phosphodiesterase V 
inhibitors and the prostacyclin analogs seem to have a place in 
the management of the ischemic ulcers of difficult treatment, 
mainly in patients with SSc.
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